Gelonghui October 8th | Johnson & Johnson stated on Monday that it has terminated late-stage studies of an experimental drug for treating bladder cancer because the drug did not show significant advantages over chemotherapy.
强生终止一种膀胱癌药物的晚期研究
Johnson & Johnson terminates late-stage study of a bladder cancer drug.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.